“Gardasil: star cancer vaccine” is a comprehensive drug report on the market leader of HPV vaccine segment (according to 2015 sales).
In this report, Gardasil and Gardasil 9 are considered as a single product as Merck & Company reports the sales of both the vaccines collectively. Gardasil is the largest oncology vaccine and the largest in Merck’s oncology product portfolio. It is classified under the vaccine therapy and belongs to the HPV vaccine class. It is indicated for the prevention of cervical, vulvar, vaginal, and anal cancers. It is also approved for non-oncology indications and is known as ‘Silgard’ in Europe.
The report gives basic information about the vaccine, covering all details from brand name, date of approvals, mechanism of action, route of administration, etc. It has an interesting infographic description of the approval timeline and contains an event tracker, which covers all the major events surrounding the vaccine, news about Gardasil, information on competitor vaccine, number of clinical trials (by year and by phase), and so on.
Request for Sample Report@http://www.aarkstore.com/sample/360027
Details of the sales analysis section
Historical annual sales analysis: Historical annual sales have been analysed with the help of graphical representation of sales over 2006 to Q3-2016. The report has all the data in tabular format as well. We have highlighted key reasons for the sales trend in all the geographies listed.
Historical quarterly sales analysis: Additionally, we have shown sales analysis on quarterly basis for the past 19 quarters from Q1-2012 to Q3-2016. The quarterly data is also in graphical as well as tabular format.
Expected sales analysis: The report has our expectations for Gardasil sales over 2016-2021. We have highlighted the key reasons for our expectations. All the historical as well as expected sales analysis is based on:
1. Total global sales
2. US sales
3. International sales (Merck sales)
Other important details
Key event tracker: The report highlights key events that have taken place for Gardasil from 2006 to 2016 (along with those events expected in 2016). It gives additional information about the key events that have driven sales for the vaccine over this period.
Clinical trial numbers: The report provides numbers of clinical trials which have started for Gardasil in 2014, 2015 and 2016 and for different phases: phase II, phase II/III and phase III. It gives insights into whether the company is still spending money for taking the vaccine even further for other indications.
Competitive vaccines: Additionally, the vaccine which compete with Gardasil for the prevention of HPV disease listed with the details including brand name, API, company involved and first approval dates. It also provides comparison between the currently prevailing HPV vaccines.
Best Selling Healthcare Market Reports :
Aarkstore Enterprise is a leading provider of business and financial information and solutions worldwide. We specialize in providing online market business information on market research reports, books, magazines, conference at competitive prices, and strive to provide excellent and innovative service to our customers.